ATAI:NASDAQ
AtaiBeckley Inc
4,20 US$
arrow_upward
+1,57%(+0,065) 1 d
4,29 US$
arrow_upward
+2,14% (+0,090)bedtimeEfter stängning
Stängd: 4 maj, 16:00:01 GMT−4 · USD
search
Alla symboler
1 d
5 d
1 m
6 m
Hittills i år
1 år
5 år
MAX
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för ATAI …
Öppen
4,11 US$
Högt
4,28 US$
Lågt
4,04 US$
Börsvärde
1,54 md
Genomsn. vol.
6,59 mn
Volym
6,99 mn
52v högst
6,72 US$
52v lägst
1,29 US$
EPS
−2,91 US$
Beta
1,59
Utestående aktier
366,92 mn
Antal anställda
99
Nyheter och artiklar
Från källor på webben
Profil
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Om AtaiBeckley Inc
AI-innehåll kan innehålla fel. Läs mer